The demo obtained equally its Key endpoints, with semaglutide 2.4 mg demonstrating statistically significant and remarkable advancements in liver fibrosis with no worsening of steatohepatitis, and resolution of steatohepatitis without any worsening of liver fibrosis in individuals with MASH when com